B-Cell Reconstitution After Hematopoietic Stem Cell Transplantation
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 主要终点
- B cells reconstitution
研究概览
简要总结
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematological malignancies. However, patients who have received this treatment have a persistent deficit in humoral immunity up to one year post-transplant. To date, the design of new therapeutic strategies to improve immune recovery in allo-HSCT patients is still hampered by the fact that post-transplant regenerative hematopoiesis has never been studied, and more generally by our currently limited knowledge on the development and function of human B lymphocytes. The main objective of our study is to study early B-cell progenitor reconstitution after allogeneic hematopoietic stem cell transplantation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age and older
- •with hematological malignancies and subject to allogeneic HSCT
- •with health insurance coverage (bénéficiaire ou ayant droit)
- •having signed a written informed consent.
- •Inclusion criteria of donor
- •18 years of age and older
- •with health insurance coverage (bénéficiaire ou ayant droit)
- •having signed a specific written informed consent.
- •Exclusion criteria of recipient and donor
- •Absence of written informed consent
- •Patient or donor on AME
- •Patient or donor on AME or under protection by law, tutorship or curatorship
- •Pregnant women
排除标准
- 未提供
结局指标
主要结局
B cells reconstitution
时间窗: at day 100 days post-transplant
B cell clusters as assess by CyTOF technology
次要结局
- Perturbations in growth or differentiation of progenitor/precursor of B cells(at 6 months post-transplant)
- B cells reconstitution(at 6 months post-transplant)